Oncotarget

Research Papers:

Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells

Remya Raja, Nandini A. Sahasrabuddhe, Aneesha Radhakrishnan, Nazia Syed, Hitendra S. Solanki, Vinuth N. Puttamallesh, Sai A. Balaji, Vishalakshi Nanjappa, Keshava K. Datta, Niraj Babu, Santosh Renuse, Arun H. Patil, Evgeny Izumchenko, T.S. Keshava Prasad, Xiaofei Chang, Annapoorni Rangarajan, David Sidransky, Akhilesh Pandey, Harsha Gowda and Aditi Chatterjee _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:61229-61245. https://doi.org/10.18632/oncotarget.11310

Metrics: PDF 1825 views  |   HTML 1510 views  |   ?  


Abstract

Remya Raja1,*, Nandini A. Sahasrabuddhe1,*, Aneesha Radhakrishnan1,2,*, Nazia Syed1,2, Hitendra S. Solanki1,3, Vinuth N. Puttamallesh1,4, Sai A. Balaji5, Vishalakshi Nanjappa1,4, Keshava K. Datta1,3, Niraj Babu1, Santosh Renuse1,4, Arun H. Patil1,3, Evgeny Izumchenko6, T.S. Keshava Prasad1,4,11,12, Xiaofei Chang6, Annapoorni Rangarajan5, David Sidransky6, Akhilesh Pandey7,8,9,10, Harsha Gowda1,11, Aditi Chatterjee1,11

1Institute of Bioinformatics, International Tech Park, Bangalore, 560 066, India

2Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry, 605014, India

3School of Biotechnology, KIIT University, Bhubaneswar, Odisha, 751024, India

4Amrita School of Biotechnology, Amrita University, Kollam, 690 525, India

5Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560012, India

6Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21231, USA

7McKusick-Nathans Institute of Genetic Medicine, Baltimore, Maryland, 21205, USA

8Department of Biological Chemistry, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA

9Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA

10Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA

11YU-IOB Center for Systems Biology and Molecular Medicine, Yenepoya University, Mangalore, 575018, India

12NIMHANS-IOB Proteomics and Bioinformatics Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences, Bangalore, 560029, India

*These authors contributed equally to this work

Correspondence to:

Aditi Chatterjee, email: aditi@ibioinformatics.org

Keywords: mass spectrometry, NSCLC, p21 (RAC1)-activated kinase 6, smoking

Received: January 27, 2016     Accepted: August 08, 2016     Published: August 16, 2016

ABSTRACT

Epidemiological data clearly establishes cigarette smoking as one of the major cause for lung cancer worldwide. Recently, targeted therapy has become one of the most preferred modes of treatment for cancer. Though certain targeted therapies such as anti-EGFR are in clinical practice, they have shown limited success in lung cancer patients who are smokers. This demands discovery of alternative drug targets through systematic investigation of cigarette smoke-induced signaling mechanisms. To study the signaling events activated in response to cigarette smoke, we carried out SILAC-based phosphoproteomic analysis of H358 lung cancer cells chronically exposed to cigarette smoke. We identified 1,812 phosphosites, of which 278 phosphosites were hyperphosphorylated (≥ 3-fold) in H358 cells chronically exposed to cigarette smoke. Our data revealed hyperphosphorylation of S560 within the conserved kinase domain of PAK6. Activation of PAK6 is associated with various processes in cancer including metastasis. Mechanistic studies revealed that inhibition of PAK6 led to reduction in cell proliferation, migration and invasion of the cigarette smoke treated cells. Further, siRNA mediated silencing of PAK6 resulted in decreased invasive abilities in a panel of non-small cell lung cancer (NSCLC) cells. Consistently, mice bearing tumor xenograft showed reduced tumor growth upon treatment with PF-3758309 (group II PAK inhibitor). Immunohistochemical analysis revealed overexpression of PAK6 in 66.6% (52/78) of NSCLC cases in tissue microarrays. Taken together, our study indicates that PAK6 is a promising novel therapeutic target for NSCLC, especially in smokers.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11310